NASDAQ:IMTX Immatics (IMTX) Stock Price, News & Analysis $11.73 +0.30 (+2.62%) (As of 09/6/2024 ET) Add Compare Share Share Today's Range$11.21▼$11.7850-Day Range$10.93▼$12.9252-Week Range$7.15▼$13.77Volume537,424 shsAverage Volume460,733 shsMarket Capitalization$993.04 millionP/E RatioN/ADividend YieldN/APrice Target$16.00 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesOptions ChainOwnershipSEC FilingsShort InterestTrendsStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesOptions ChainOwnershipSEC FilingsShort InterestTrends Get Immatics alerts: Email Address Immatics MarketRank™ Stock AnalysisAnalyst RatingBuy3.00 Rating ScoreUpside/Downside36.4% Upside$16.00 Price TargetShort InterestBearish12.17% of Shares Sold ShortDividend StrengthN/ASustainabilityN/ANews Sentiment0.15Based on 4 Articles This WeekInsider TradingN/AProj. Earnings GrowthDecreasingFrom ($1.03) to ($1.22) Per ShareSee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.1.04 out of 5 starsMedical Sector752nd out of 910 stocksBiological Products, Except Diagnostic Industry125th out of 155 stocks 3.5 Analyst's Opinion Consensus RatingImmatics has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 2 buy ratings, no hold ratings, and no sell ratings.Amount of Analyst CoverageImmatics has only been the subject of 1 research reports in the past 90 days.Read more about Immatics' stock forecast and price target. Previous Next 0.0 Short Interest Percentage of Shares Shorted12.17% of the outstanding shares of Immatics have been sold short.Short Interest Ratio / Days to CoverImmatics has a short interest ratio ("days to cover") of 24.6, which indicates bearish sentiment.Change versus previous monthShort interest in Immatics has recently increased by 0.19%, indicating that investor sentiment is decreasing. Previous Next 0.0 Dividend Strength Dividend YieldImmatics does not currently pay a dividend.Dividend GrowthImmatics does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for IMTX. Previous Next 2.9 News and Social Media Coverage News SentimentImmatics has a news sentiment score of 0.15. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.55 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 4 news articles for Immatics this week, compared to 1 article on an average week.Search Interest4 people have searched for IMTX on MarketBeat in the last 30 days. This is an increase of 300% compared to the previous 30 days.MarketBeat Follows1 people have added Immatics to their MarketBeat watchlist in the last 30 days. Previous Next 1.7 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Immatics insiders have not sold or bought any company stock.Percentage Held by InsidersOnly 3.30% of the stock of Immatics is held by insiders.Percentage Held by Institutions64.41% of the stock of Immatics is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about Immatics' insider trading history. Previous Next 0.0 Earnings and Valuation Earnings GrowthEarnings for Immatics are expected to decrease in the coming year, from ($1.03) to ($1.22) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Immatics is -11.07, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Immatics is -11.07, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioImmatics has a P/B Ratio of 2.38. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.Read more about Immatics' valuation and earnings. Previous Next See Top Rated MarketRank™ Stocks Here Ad Porter & CompanyWar on Elon Escalates… A radical, potentially game-changing technology that threatens to destroy the trillion-dollar, “green energy” grift of the elites. And yet, while it threatens their wealth and power, it could be transformational for both the U.S. economy and your wealth.One company holds a near-total monopoly on it. About Immatics Stock (NASDAQ:IMTX)Immatics N.V., a clinical-stage biopharmaceutical company, focuses on the research and development of potential T cell redirecting immunotherapies for the treatment of cancer in the United States. The company is developing targeted immunotherapies with a focus on treating solid tumors through two distinct treatment modalities, such as TCR-engineered autologous or allogeneic adoptive cell therapies (ACT) and antibody-like TCR Bispecifics. Its products pipeline includes IMA203 that targets solid tumors, which is in Phase 1b clinical trial; IMA203CD8, a cell therapy product that is in Phase 1b clinical trial; IMA204 that targets tumor stroma, which is in preclinical stage; and IMA30x, an allogenic cellular therapy product candidate, which is in preclinical stage. The company also develops TCR Bispecifics products, including IMA401 and IMA402, which is in Phase 1a clinical trial. The company has a strategic collaboration agreement with MD Anderson Cancer Center to develop multiple T cell and TCR-based adoptive cellular therapies; Celgene Corporation to develop novel adoptive cell therapies targeting multiple cancers; and Genmab A/S to develop T cell engaging bispecific immunotherapies targeting multiple cancer indications. Immatics N.V. is headquartered in Tübingen, Germany.Read More IMTX Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart IMTX Stock News HeadlinesSeptember 6 at 7:00 AM | globenewswire.comImmatics Announces Upcoming Oral Presentation at the Society for Melanoma Research Congress 2024September 6 at 4:31 AM | americanbankingnews.comImmatics (NASDAQ:IMTX) Given "Overweight" Rating at Cantor FitzgeraldSeptember 7, 2024 | Porter & Company (Ad)War on Elon Escalates… A radical, potentially game-changing technology that threatens to destroy the trillion-dollar, “green energy” grift of the elites. And yet, while it threatens their wealth and power, it could be transformational for both the U.S. economy and your wealth.August 16, 2024 | finance.yahoo.comImmatics Second Quarter 2024 Earnings: Beats ExpectationsAugust 16, 2024 | markets.businessinsider.comBuy Rating for Immatics: Promising Clinical Trials and Strong Financials Signal Upside PotentialAugust 16, 2024 | markets.businessinsider.comBuy Rating Justified by Immatics’ Advancing Pipeline and Strategic Financial PositionAugust 15, 2024 | markets.businessinsider.comBuy Rating Affirmed on Immatics’ Promising Pipeline and Upcoming Data CatalystsAugust 13, 2024 | globenewswire.comImmatics Announces Second Quarter 2024 Financial Results and Business UpdateSeptember 7, 2024 | Porter & Company (Ad)War on Elon Escalates… A radical, potentially game-changing technology that threatens to destroy the trillion-dollar, “green energy” grift of the elites. And yet, while it threatens their wealth and power, it could be transformational for both the U.S. economy and your wealth.July 31, 2024 | finance.yahoo.comImmatics Appoints Alise Reicin to Board of DirectorsJuly 25, 2024 | finance.yahoo.comInvestors in Immatics (NASDAQ:IMTX) have seen returns of 24% over the past five yearsJuly 22, 2024 | markets.businessinsider.comHere's Why 'Trend' Investors Would Love Betting on ImmaticsJuly 19, 2024 | finance.yahoo.comImmatics Announces Upcoming Oral Presentation at ESMO Congress 2024May 21, 2024 | finance.yahoo.comHere's Why We're Not Too Worried About Immatics' (NASDAQ:IMTX) Cash Burn SituationMay 16, 2024 | markets.businessinsider.comBuy Rating Affirmed for Immatics on Strong TCR-T Cell Therapy Data and Promising OutlookMay 16, 2024 | msn.comStock Market News for May 15, 2024May 14, 2024 | globenewswire.comImmatics Announces First Quarter 2024 Financial Results and Business UpdateMarch 29, 2024 | markets.businessinsider.comMaintained Buy Rating for Immatics Amid Robust Clinical Pipeline and Promising PartnershipsSee More Headlines Receive IMTX Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Immatics and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings8/13/2024Today9/07/2024Next Earnings (Estimated)11/12/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Biological products, except diagnostic Sub-IndustryPharmaceutical Products Current SymbolNASDAQ:IMTX CUSIPN/A CIK1809196 Webwww.immatics.com Phone4.97072E+12FaxN/AEmployees260Year FoundedN/APrice Target and Rating Average Stock Price Target$16.00 High Stock Price Target$16.00 Low Stock Price Target$16.00 Potential Upside/Downside+36.4%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage2 Analysts Profitability EPS (Most Recent Fiscal Year)($1.06) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-104,980,000.00 Net Margins-103.99% Pretax Margin-101.82% Return on Equity-23.34% Return on Assets-13.22% Debt Debt-to-Equity RatioN/A Current Ratio3.74 Quick Ratio3.74 Sales & Book Value Annual Sales$70.87 million Price / Sales14.01 Cash FlowN/A Price / Cash FlowN/A Book Value$4.93 per share Price / Book2.38Miscellaneous Outstanding Shares84,658,000Free Float81,864,000Market Cap$993.04 million OptionableOptionable Beta0.75 Metaverse Stocks And Why You Can't Ignore ThemThinking about investing in Meta, Roblox, or Unity? Click the link to learn what streetwise investors need to know about the metaverse and public markets before making an investment.Get This Free Report Key ExecutivesDr. Harpreet Singh Ph.D. (Age 49)CEO, MD, Member of Management Board & Executive Director Comp: $896.49kDr. Toni Weinschenk Ph.D. (Age 50)Co-Founder & Chief Innovation Officer Mr. Arnd Christ MBA (Age 58)Chief Financial Officer Mr. Steffen Walter Ph.D. (Age 47)Chief Operations Officer Mr. Edward A. Sturchio J.D. (Age 48)General Counsel & Secretary Dr. Carsten Reinhardt M.D. (Age 57)Ph.D., Chief Development Officer Mr. Cedrik M. Britten M.D. (Age 48)Chief Medical Officer Mr. Jordan Silverstein (Age 44)Head of Strategy Dr. Hans-Georg Rammensee Ph.D.Co-Founder & Member of the Scientific Advisory BoardMr. Ephraim Hofsäß M.Sc.Vice President of SEC Reporting & AccountingMore ExecutivesKey CompetitorsBiohavenNYSE:BHVNArcellxNASDAQ:ACLXTG TherapeuticsNASDAQ:TGTXIDEAYA BiosciencesNASDAQ:IDYAHUTCHMEDNASDAQ:HCMView All CompetitorsInstitutional OwnershipPerceptive Advisors LLCBought 3,503,750 shares on 8/16/2024Ownership: 9.552%Frazier Life Sciences Management L.P.Bought 1,152,456 shares on 8/16/2024Ownership: 1.361%Algert Global LLCBought 20,818 shares on 8/16/2024Ownership: 0.025%Forefront Analytics LLCBought 11,987 shares on 8/16/2024Ownership: 0.014%Quarry LPBought 8,500 shares on 8/16/2024Ownership: 0.010%View All Institutional Transactions IMTX Stock Analysis - Frequently Asked Questions How have IMTX shares performed this year? Immatics' stock was trading at $10.53 at the start of the year. Since then, IMTX stock has increased by 11.4% and is now trading at $11.73. View the best growth stocks for 2024 here. How were Immatics' earnings last quarter? Immatics (NASDAQ:IMTX) released its earnings results on Tuesday, August, 13th. The company reported ($0.18) earnings per share for the quarter, beating analysts' consensus estimates of ($0.35) by $0.17. The business earned $20.19 million during the quarter, compared to the consensus estimate of $12.36 million. Immatics had a negative net margin of 103.99% and a negative trailing twelve-month return on equity of 23.34%. Who are Immatics' major shareholders? Top institutional shareholders of Immatics include Perceptive Advisors LLC (9.55%), Frazier Life Sciences Management L.P. (1.36%), Sofinnova Investments Inc. (0.94%) and TD Asset Management Inc (0.42%). How do I buy shares of Immatics? Shares of IMTX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. What other stocks do shareholders of Immatics own? Based on aggregate information from My MarketBeat watchlists, some other companies that Immatics investors own include Advanced Micro Devices (AMD), Chimerix (CMRX), Datadog (DDOG), Forte Biosciences (FBRX) and This page (NASDAQ:IMTX) was last updated on 9/7/2024 by MarketBeat.com Staff From Our PartnersPerfect Crypto Buying Opportunity for 50 CentsWhen cryptos take a hit, the mom and pop investors run for the hills. But the top investors keep buying wit...Crypto 101 Media | SponsoredThe solution to fast food’s wage hike crisisShake Shack will be closing six California locations in response to the recent $20/hour minimum wage increase,...Deal Maker | SponsoredPre-IPO| 32,481% Growth: First Disruption to $martphones in 15 Years🤳45M Users | 32,481% Growth Rate Get in on the biggest disruption to smartphones in over a decade. Reg A inv...Mode Mobile | SponsoredTim Sykes’ Urgent Trade Alert: “Make this move now”WARNING: 80 Wall Street banks are gearing up for MASSIVE D.C. shock This $2 trillion D.C. shock is NOT abou...Timothy Sykes | SponsoredBiden’s Capital Gains Tax to Devastate Savings!Don't let the corrupt elites dictate your future—ACT NOW! This guide is your first step towards financial inde...Golden Crest | SponsoredChina Stockpiling Gold “Like No Tomorrow”For 18 consecutive months, China’s central bank has increased its gold reserve. The country, with a populat...True Gold Republic | SponsoredThe death of Nvidia?Today, I’m warning of another looming catastrophe. Only this time, it’s not in pot stocks, cryptos, or U.S....Porter & Company | SponsoredSay Goodbye to the US DollarThe warning signs are everywhere… According to experts, the United States Dollar is "as good as doomed." ...Sasco Gold LLC | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Immatics Please log in to your account or sign up in order to add this asset to your watchlist. Share Immatics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
